OncoCyte

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IRVINE, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, announced today that its management team will participate at the following conferences:

Oncocyte to Participate at Upcoming Investor Conferences

IRVINE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation  (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced the appointment of John Peter (JP) Gutfreund as an independent member of its board of directors, effective July 28, 2022.

Oncocyte Announces the Appointment of John Peter Gutfreund as Independent Member of Its Board of Directors Effective July 28, 2022

NEW YORK , July 28, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of OncoCyte Corporation (NASDAQ: OCX). If you are a shareholder of OncoCyte Corporation and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at: http://pjlfirm.com/oncocyte-corporation/ You may also contact Robert H.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating OncoCyte Corporation for Potential Breaches of Fiduciary Duty By Its Board of Directors

IRVINE, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, announced today that it will release its second quarter 2022 financial results on Wednesday, August 10, 2022. In conjunction with the release, Oncocyte will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Oncocyte to Announce Second Quarter 2022 Financial Results

OncoCyte (OCX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

OncoCyte (OCX) Upgraded to Buy: Here's What You Should Know

IRVINE, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), is a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced that it will host a key opinion leader (KOL) webinar on the role of DetermalO™ and the tumor microenvironment in clinical practice on Tuesday, June 28, 2022, at 10:00am Eastern Time. To register for the webinar, please click here.

Oncocyte Hosting Key Opinion Webinar on the Role of DetermaIO and the Tumor Microenvironment in Clinical Practice

DetermaIO identifies responders to immunotherapy among the 95% of patients with colon cancer currently ineligible for treatment based on existing biomarker, addressing a significant unmet need

Oncocyte Presents DetermaIO™ Data at ASCO 2022 Supporting the Test's Potential to Expand the Clinical Use of Immunotherapy

OncoCyte Corporation (NASDAQ:OCX ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Ronnie Andrews – President and Chief Executive Officer Mitch Levine – Chief Financial Officer Troy Williams – LifeSci Advisors Conference Call Participants Mike Matson – Needham & Company Mark Massaro – BTIG David Westenberg – Piper Sandler Paul Knight – KeyBanc Capital Markets Thomas Flaten – Lake Street Capital Markets Mason Carrico – Stephens Inc. Bruce Jackson – The Benchmark Company Operator Greetings and welcome to the Oncocyte Corporation First Quarter of 2022 Earnings Conference Call. At this time, all participants are in listen-only mode.

OncoCyte Corporation (OCX) CEO Ronnie Andrews on Q1 2022 Results - Earning Calls Transcript

OncoCyte (OCX) delivered earnings and revenue surprises of 15.38% and 16.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

OncoCyte (OCX) Reports Q1 Loss, Lags Revenue Estimates

Digital PCR format allows for rapid turnaround time to facilitate fast and accurate post-transplant treatment decisions Digital PCR format allows for rapid turnaround time to facilitate fast and accurate post-transplant treatment decisions

Oncocyte Completes Validation of TheraSure™ Transplant Monitor Test

We circle back on OncoCyte Corp. for the first time in just over one year. This oncology diagnostic concern has several new products it plans to launch on the near-term horizon.

Revisiting OncoCyte Corp.

IRVINE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, announced today that it will release its first quarter 2022 financial results on Wednesday, May 11, 2022. In conjunction with the release, Oncocyte will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Oncocyte to Announce First Quarter 2022 Financial Results

Data points to accuracy of IO Score and provides grounds for its further use to evaluate response to immune checkpoint therapies for patients with colorectal, gastric and breast cancers Data points to accuracy of IO Score and provides grounds for its further use to evaluate response to immune checkpoint therapies for patients with colorectal, gastric and breast cancers

Oncocyte to Present New Data at ASCO 2022 Underpinning Pan-Cancer Clinical Utility of DetermaIO™

IRVINE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), (“Oncocyte” or the “Company”), announced today the pricing of an underwritten public offering of 26,266,417 shares of its common stock, together with warrants to purchase up to an aggregate of 13,133,208.5 shares of its common stock. Each share of common stock is being sold together with one warrant to purchase 0.5 shares of common stock at a combined offering price of $1.3325 for total gross proceeds of approximately $35 million, before underwriting discounts and commissions and offering expenses payable by Oncocyte. The warrants have an exercise price of $1.53 per share, are exercisable immediately, and will expire five years following the date of issuance. The offering is expected to close on or about April 19, 2022, subject to the satisfaction or waiver of customary closing conditions.

Oncocyte Corporation Announces Pricing of Public Offering of Common Stock and Warrants

IRVINE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), (“Oncocyte” or the “Company”), announced today that it has commenced an underwritten public offering of shares of its common stock, together with warrants to purchase additional shares of its common stock. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock and/or additional warrants to purchase shares of common stock to be issued and sold in the public offering, in any combination thereof, on the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering, the offering price of the common stock and warrants, or the exercise price of the warrants.

Oncocyte Corporation Announces Proposed Public Offering of Common Stock and Warrants

IRVINE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), (“Oncocyte” or the “Company”), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient cancer care journey, announced today the pricing of a registered direct offering of 11,765 shares of its Series A Convertible Preferred Stock (the “Preferred Stock”) with institutional investors. The shares of Preferred Stock are convertible into a total of 7,689,542 shares of our common stock, at a conversion price of $1.53. The Preferred Stock will bear a dividend of 6% per annum and is required to be redeemed by the Company, if not converted, on April 8, 2024. Gross proceeds from the offering are expected to be approximately $10 million, before deducting offering expenses. There is no established public trading market for the Preferred Stock and we do not intend to apply for listing of the Preferred Stock on any national securities exchange or expect a market to development.

Oncocyte Corporation Announces Pricing of Registered Direct Offering of 11,765 Shares of Series A Convertible Preferred Stock

Poster outlines data showing Oncocyte's DetermaIO™ tool can inform therapeutic decisions and has the potential to improve outcomes for patients with bladder cancer

Oncocyte to Present New Data Confirming Association of IO Score with Response to Immunotherapy Treatment for Bladder Cancer at the American Association for Cancer Research Annual Meeting 2022

OncoCyte (OCX) delivered earnings and revenue surprises of 0% and -17.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

OncoCyte (OCX) Q4 Earnings Match Estimates, Revenues Lag (Revised)

OncoCyte Corporation (OCX) CEO Ronnie Andrews on Q4 2021 Results - Earnings Call Transcript

OncoCyte (OCX) delivered earnings and revenue surprises of -20% and 17.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

OncoCyte (OCX) Reports Q4 Loss, Lags Revenue Estimates

Collaboration extends global reach for Thermo Fisher's rapid next-generation sequencing technology

Oncocyte Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific to Expand Access to Precision Oncology

Data supports the use of DetermaIO as a pan-cancer diagnostic tool, now addressing an unmet need for patients with triple negative breast cancer, the most aggressive type of breast cancer

Spotlight Poster Presentation at San Antonio Breast Cancer Symposium SABCS 2021 Shows Oncocyte's DetermaIO™ Clinical Test Predicts Response to Immunotherapy in Triple Negative Breast Cancer

Spotlight poster presentation indicates DetermaIO assay and algorithm is robust across multiple diagnostic platforms, confirms that test predicts response to immunotherapy (atezolizumab) benefit

Oncocyte to Present New Data on DetermaIO Clinical Test for Immunotherapy Response in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium 2021

OncoCyte's (OCX) CEO Ronnie Andrews on Q3 2021 Results - Earnings Call Transcript

OncoCyte (OCX) delivered earnings and revenue surprises of -57.14% and -69.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

News for OncoCyte Stock (OCX)